Study to Evaluate the Safety and Tolerability of AD-NP1 in Healthy Human Adult Volunteers

This is a Phase 1 single‐blind, placebo‐controlled, dose‐escalation study designed toevaluate the safety of AD‐NP1, a humanized monoclonal antibody targeting humanectonucleotide pyrophosphatase/phosphodiesterase‐1 (ENPP1). The study aims to assess themaximum tolerated dose (MTD), pharmacokinetics (PK), pharmacodynamics (PD), andimmunogenicity of AD‐NP1 in healthy volunteers. Participants will be randomized toreceive either AD‐NP1 or placebo, with safety and efficacy monitored in accordance withGood Clinical Practice (GCP) guidelines. The study also seeks to explore changes inhealth‐related quality of life (HRQOL) during the trial.